127 related articles for article (PubMed ID: 7536091)
21. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
[TBL] [Abstract][Full Text] [Related]
22. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
[TBL] [Abstract][Full Text] [Related]
24. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen screening and mortality from prostate cancer.
Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
[TBL] [Abstract][Full Text] [Related]
27. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
[TBL] [Abstract][Full Text] [Related]
28. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
Sirovich BE; Schwartz LM; Woloshin S
JAMA; 2003 Mar; 289(11):1414-20. PubMed ID: 12636464
[TBL] [Abstract][Full Text] [Related]
29. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium.
Arch Intern Med; 1995 Feb; 155(4):389-92. PubMed ID: 7531426
[TBL] [Abstract][Full Text] [Related]
30. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
31. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
[TBL] [Abstract][Full Text] [Related]
32. Knowledge, attitudes, and screening practices among older men regarding prostate cancer.
Steele CB; Miller DS; Maylahn C; Uhler RJ; Baker CT
Am J Public Health; 2000 Oct; 90(10):1595-600. PubMed ID: 11029994
[TBL] [Abstract][Full Text] [Related]
33. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
34. Trends in prostate-specific antigen testing from 1995 through 2004.
Farwell WR; Linder JA; Jha AK
Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173
[TBL] [Abstract][Full Text] [Related]
35. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
Kopec JA; Goel V; Bunting PS; Neuman J; Sayre EC; Warde P; Levers P; Fleshner N
J Urol; 2005 Aug; 174(2):495-9; discussion 499. PubMed ID: 16006879
[TBL] [Abstract][Full Text] [Related]
36. Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database.
D'Ambrosio GG; Campo S; Cancian M; Pecchioli S; Mazzaglia G
Eur J Cancer Prev; 2010 Nov; 19(6):413-6. PubMed ID: 20679895
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
38. Evidence of prostate cancer screening in a UK region.
Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen screening: An update of physician beliefs and practices.
Hall IJ; Rim SH; Massetti GM; Thomas CC; Li J; Richardson LC
Prev Med; 2017 Oct; 103():66-69. PubMed ID: 28793236
[TBL] [Abstract][Full Text] [Related]
40. PSA screening among elderly men with limited life expectancies.
Walter LC; Bertenthal D; Lindquist K; Konety BR
JAMA; 2006 Nov; 296(19):2336-42. PubMed ID: 17105796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
